Schroders plc increases stake in Quantum Pharma plc above 5%

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

Quantum Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Type 1 disclosure as per the Transparency Directive II Regulation

ü

3. Full name of person(s) subject to the
notification obligation:

Schroders plc & Schroder Investment Management Limited

4. Full name of shareholder(s)
(if different from 3.):

5. Date of the transaction and date on
which the threshold is crossed or
reached:

24.11.16

6. Date on which issuer notified:

25.11.16

7. Threshold(s) that is/are crossed or
reached:

Above 5%



8. Notified details:

A: Voting rights attached to shares

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary

Below 5%

Below 5%

8,469,500

N/A

8,469,500

N/A

5.008%

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Quantum Pharma Plc

    More articles like this

    Quantum Pharma Plc

    Quantum Pharma Plc FY17 Results – A Year of Change

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31, 2017. Net sales grew by 28%

    Quantum Pharma Plc

    Quantum Pharma PLC makes strategic financial appointment

    County Durham based Quantum Pharma has bolstered its executive team with the help of business advisers UNW. The niche pharmaceutical developer and manufacturer, which supplies a range of innovative products to wholesalers, retailers and hospitals, approached

    Quantum Pharma Plc

    Quantum Pharma reduces debt after taking strategic action

    Niche pharma firm Quantum Pharma says it is on target to meet market expectations after taking action to tighten its focus. The Burnopfield pharmaceutical developer , manufacturer and supplier issued a trading update for the year

    Quantum Pharma Plc

    Quantum Pharma PLC Pre-close trading update – on plan

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has released a pre-close trading update this morning. Zeus Capital said: The Board has indicated that adjusted EBITDA

    Quantum Pharma Plc

    Quantum Pharma Plc CFO purchases shares in the PLC

    Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that Gerard Murray, Quantum’s Chief Financial Officer

    DirectorsTalk

    Quantum Pharma Plc “A good first half year”

    Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has today given DirectorsTalk its half year results for the six months to 31 July 2015,